Utah Medical Products, Inc. (UTMD) reported a decline in financial performance for the third quarter and first nine months of 2025, as detailed in its latest 10-Q filing. For the three months ended September 30, 2025, the company generated net sales of $9.812 million, a decrease of 1.9% from $10.005 million in the same period of 2024. The nine-month figures also reflected a decline, with sales totaling $29.475 million, down 7.2% from $31.745 million in the prior year. Gross profit for the third quarter was $5.604 million, down 3.4% year-over-year, while net income fell by 26.2% to $2.631 million compared to $3.563 million in the third quarter of 2024.

The decline in revenue and profitability was attributed to several factors, including the cancellation of orders by two overseas distributors, which resulted in a loss of $581,000 in revenue for the third quarter. Additionally, a bad debt reserve of $395,000 was established due to the cancellation of a non-cancellable order, further impacting operating income. The company also faced increased manufacturing costs due to tariffs on imported components, which contributed to a decrease in gross profit margins. Operating income for the third quarter was reported at $2.611 million, down 21.9% from the previous year.

In terms of operational developments, UTMD's total assets as of September 30, 2025, were $121.975 million, a slight decrease from $122.538 million at the end of 2024. The company maintained a strong cash position, with cash and investments totaling $84.267 million, up from $82.976 million at the end of the previous year. The company’s stockholders' equity increased to $118.252 million, reflecting a solid financial foundation despite the decline in sales and earnings. The number of shares outstanding decreased to 3.204 million, down from 3.335 million at the end of 2024, as the company continued its share repurchase program.

Looking ahead, UTMD's management has adjusted its revenue expectations for the full year 2025, now anticipating a decline of 6-7% compared to 2024, primarily due to the impact of tariffs and changes in demand from overseas distributors. The company plans to continue leveraging its operational synergies and focus on product development, particularly in the biopharmaceutical sector. Management remains committed to returning cash to shareholders through dividends and share repurchases while exploring potential acquisition opportunities to enhance growth. The outlook for earnings per share is projected to be in the range of $3.40 to $3.50 for the year.

About UTAH MEDICAL PRODUCTS INC

Utah Medical Products, Inc. designs and manufactures high-quality, safety-focused medical devices primarily for critical care, obstetrics, neonatal intensive care, gynecology, and urology. Its core offerings include fetal monitoring accessories, neonatal catheters, gynecological electrosurgical tools, and contraceptive devices like the Filshie clip. The company serves global markets through direct sales, distributors, and OEM partnerships, emphasizing clinical utility, reliability, and regulatory compliance.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-Q Filings

A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.

Key points about the 10-Q:

  • Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
  • Content: It includes:
    • Financial statements showing the company's current financial position
    • Updates from management on the performance and projections of the business
    • Information about potential risks the company faces
    • Details on how the company is run internally
  • Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.